Cetuximab for patients with metastatic colorectal cancer - From the result of recent clinical trials

Research output: Contribution to journalArticle

Abstract

Cetuximab is a monoclonal antibody that inhibits human epidermal growth factor receptor, and was approved for metastatic advanced colorectal cancer (mCRC) in 2008 in Japan. Evidences confirming the efficacy of cetuximab have been accumulated in western countries. As the first- and second-line therapy, cetuximab plus chemotherapy showed longer survival compared with chemotherapy alone. As a third-line chemotherapy, among various anti-cancer agents for mCRC, only cetuximab could exhibit survival benefits in monotherapy or combination therapy with irinotecan. Recent studies suggest that the status of KRAS mutation is a predictive marker in colorectal cancer patients treated with cetuximab, and these findings lead to personalized cancer treatment.

Original languageEnglish
Pages (from-to)782-786
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume37
Issue number5
Publication statusPublished - 2010

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cetuximab for patients with metastatic colorectal cancer - From the result of recent clinical trials'. Together they form a unique fingerprint.

  • Cite this